Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
<b>Introduction</b>: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. <b>Purpose</b>: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatelet drugs, aft...
Saved in:
Main Authors: | Fadel Bahouth, Boris Chutko, Haitham Sholy, Sabreen Hassanain, Gassan Zaid, Evgeny Radzishevsky, Ibrahem Fahmwai, Mahmod Hamoud, Nemer Samnia, Johad Khoury, Idit Dobrecky-Mery |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-05-01
|
Series: | Medicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2305-6320/12/2/13 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01) -
Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01) -
P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01) -
Use of antiplatelet agents in patients after myocardial infarction followed up in Moscow outpatient clinics. Results of a non-interventional prospective study
by: A. I. Sapina, et al.
Published: (2024-04-01) -
NEW ANTIPLATELET DRUGS (PART 1)
by: A. B. Sumarokov
Published: (2016-01-01)